Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ (²¹²Pb-DOTAMTATE) in Adult Subjects With SSTR positive NET

Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez Journal of Nuclear Medicine, January 2022, jnumed.121.263230; DOI:

What is Alpha-emitter PRRT? 

Substitution of an alpha emitter (e.g. ²¹²Pb) for the beta emitters currently being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer (LET) and a shorter path length. Higher LET particles should cause more tumour cell death. Shorter path length should result in less collateral damage of the normal tissue and therefore less side effects for subjects receiving the drug.

Trial Summary

AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs). Because 212Pb is an in vivo generator of alpha particles, it is particularly suitable for SSTR therapy applications, i.e. it’s a type of PRRT. 

This drug addresses an unmet need in the field of peptide receptor radionuclide therapy (PRRT) for NETs. Substitution of an alpha emitter (²¹²Pb) for the beta emitters currently being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer (LET) and a shorter path length. Higher LET particles should cause more tumor cell death. A shorter path length should result in less collateral damage to the normal tissue and therefore fewer side effects for subjects receiving the drug.

The phase 1 trial completed in July 2022 and we await news on any early Phase 2 data.

A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naive Subjects With Somatostatin Receptor Expressing Neuroendocrine Tumors. 

Actual Study Start Date :December 21, 2021
Estimated Primary Completion Date :December 1, 2022
Estimated Study Completion Date :December 1, 2023

Read more detail about the phase 2 trial announcement by clicking here

Source: Targeted Alpha-Emitter Therapy With 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial

Ebrahim S DelpassandIzabela TworowskaRouzbeh EsfandiariJulien TorgueJason HurtAfshin Shafie and Rodolfo Núñez

The source document above includes a picture of one patient from Phase 1 who appears to have had a great response (a lung NET) but remember, this may not be the same response in all participants. 

Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez Journal of Nuclear Medicine, January 2022, jnumed.121.263230; DOI:

Read more here

1.  Phase 1 Identifier:  NCT03466216
2.  Phase 2 Identifier: NCT05153772
3.  Targeted Alpha Therapy (PRRT) blog post – click here

Click on the picture to read more

Other trials for Alpha-Emitter PRRT

The industry has settled on two different radionuclides so far, AC225 and Pb212.  This blog post covers 212Pb but AC225 is also another option.  The biggest trial is contained in this post below.  Click here or on the picture to read more.

Click the picture to read more

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 



I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.


Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product.  Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document  Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


Pancreatic NET with carcinoid syndrome – not as common as you think

Why do I need to write about this? I’ve been watching confusion surrounding symptomatic pancreatic NETs for years and it never ceases to amaze me

Read More »

A spotlight on Appendiceal Neuroendocrine Neoplasms

What are Appendiceal NENs Appendiceal Neuroendocrine Neoplams (NENs) account for approximately  60% of all primary cancers in the appendix.  The other main cancer types found

Read More »

Nuclidium wins award to study NET radiopharmaceutical – Phase 1 Clinical Trial of TraceNET (TM)

What is TraceNETTM TraceNETTM is a a novel copper-based ‘radiodiagnostic’ for detecting neuroendocrine tumours (NET). The PET imaging agent candidate is the diagnostic component of

Read More »

Experimental drug for Gastric NET – Netazepide

Gastric NETs When I wrote my post entitled “Spotlight on Gastric Neuroendocrine Neoplasms“, I explained what these were with some emphasis on the association with

Read More »

A Newsletter from RonnyAllan.NET – 13th March 2023

Newsletter from Ronny Allan – 13th March 2023 Welcome to my new template newsletter compiled using WordPress (my blog app). This is the 2nd in

Read More »

Fructose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember all sorts of ‘plumbing’ issues but was told it would take

Read More »

A tribute to the life and legacy of Miranda Filmer

It’s true to say that Neuroendocrine Cancer is an older person’s disease, the epidemiology is clear on that.  But I do see many young people

Read More »

Treatment for Neuroendocrine Cancer: Beware of the alternatives

The Alternative Hype Cancer Research UK warns of the risks in Alternative Therapies, and I pay great attention to what these guys say.  I know

Read More »

RonnyAllan.NET – Summary of February 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Another great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any

Read More »

One thought on “Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ (²¹²Pb-DOTAMTATE) in Adult Subjects With SSTR positive NET

I love comments - feel free!

%d bloggers like this: